Abstract
What Is the CADTH Reimbursement Recommendation for Trikafta?
 
 CADTH recommends that Trikafta be reimbursed by public drug plans for the treatment of cystic fibrosis (CF) in patients aged 2 to 5 years and older who have at least one F508del mutation in the CFTR gene, if certain conditions are met. The previous recommendation for Trikafta, for patients who initiate treatment at age 6 years or older, continues to apply to those patients.
 Patients who start treatment with Trikafta should be evaluated for response after 1 year, and the treating physician must provide evidence after that the patient is benefiting from the treatment. The cost of Trikafta must also be reduced.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
